靶向RGD结合整合素作为糖尿病视网膜病变和新生血管性年龄相关性黄斑变性的整合疗法
本综述聚焦RGD结合整合素在糖尿病视网膜病变(DR)、糖尿病黄斑水肿(DME)和新生血管性年龄相关性黄斑变性(nvAMD)等复杂多因素视网膜疾病中的病理生理作用,总结其与生长因子、细胞因子和酶的相互作用,并讨论靶向RGD结合整合素在DME和nvAMD中的近期临床进展及未来潜力。
要点
- RGD结合整合素参与DR和nvAMD的关键疾病标志:炎症、血管渗漏、血管生成和纤维化。
- 靶向整合素相关通路可能同时阻断多个致盲性病理途径。
- 综述讨论了靶向RGD结合整合素在DME和nvAMD中的近期临床进展。
核心结论
- RGD结合整合素在DR和nvAMD的多种关键病理过程中起重要作用,靶向这些整合素相关通路具有同时阻断炎症、血管渗漏、血管生成和纤维化的治疗潜力。
研究设计与样本
- 本文为综述,聚焦RGD结合整合素在DR、DME和nvAMD中的病理生理作用、分子通路调控及近期临床进展。
主要发现
- 广泛证据表明RGD结合整合素参与DR和nvAMD的关键疾病标志,包括炎症、血管渗漏、血管生成和纤维化。
- 综述总结了整合素与生长因子、细胞因子和酶等关键分子之间的相互作用。
- 文章讨论了靶向RGD结合整合素在DME和nvAMD背景下的近期临床进展及限制疾病进展的未来潜力。
临床怎么用
- 基于整合素在DR和nvAMD多种致盲性病理通路中的作用,靶向RGD结合整合素相关通路可能成为同时干预多条病理途径的整合治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Integrins are a class of transmembrane receptors that are involved in a wide range of biological functions. Dysregulation of integrins has been implicated in many pathological processes and consequently, they are attractive therapeutic targets. In the ophthalmology arena, there is extensive evidence suggesting that integrins play an important role in diabetic retinopathy (DR), age-related macular degeneration (AMD), glaucoma, dry eye disease and retinal vein occlusion. For example, there is extensive evidence that arginyl-glycyl-aspartic acid (Arg-Gly-Asp; RGD)-binding integrins are involved in key disease hallmarks of DR and neovascular AMD (nvAMD), specifically inflammation, vascular leakage, angiogenesis and fibrosis. Based on such evidence, drugs that engage integrin-linked pathways have received attention for their potential to block all these vision-threatening pathways. This review focuses on the pathophysiological role that RGD-binding integrins can have in complex multifactorial retinal disorders like DR, diabetic macular edema (DME) and nvAMD, which are leading causes of blindness in developed countries. Special emphasis will be given on how RGD-binding integrins can modulate the intricate molecular pathways and regulate the underlying pathological mechanisms. For instance, the interplay between integrins and key molecular players such as growth factors, cytokines and enzymes will be summarized. In addition, recent clinical advances linked to targeting RGD-binding integrins in the context of DME and nvAMD will be discussed alongside future potential for limiting progression of these diseases.
引用
- Van Hove I, Hu TT, Beets K, et al. Targeting RGD-binding integrins as an integrative therapy for diabetic retinopathy and neovascular age-related macular degeneration. Prog Retin Eye Res. 2021. PMID: 33775825. doi:10.1016/j.preteyeres.2021.100966
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。